CHO V10
Alternative Names: CHO-V10; V-10Latest Information Update: 10 May 2023
At a glance
- Originator CHO Pharma
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 05 May 2023 CHO Pharma has patent pending for CHOptimaxTM in multiple countries worldwide, as of May 2023
- 05 May 2023 CHO Pharma has patent protection for CHOptimaxTM in multiple countries worldwide, as of May 2023
- 13 Feb 2023 Pharmacodynamics data from preclinical trial in COVID-2019 infections released by CHO Pharma, prior to May 2021 (CHO Pharma website, February 2023)